Search Results for "Benzodiazepine Multiple Sclerosis"

00:04 EDT 21st September 2014 | BioPortfolio

Original Source: Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis

This study will use positron emission tomography (PET) to measure a brain protein called peripheral benzodiazepine receptor (PBR) in patients with multiple sclerosis. PBR is created during the inflammation process, and brain inflammation is a key feature of multiple sclerosis (MS). PBR usually affects one type of brain cell, but it can also cause damage to surrounding areas of the brain in patients with MS. PET studies of PBRs and brain inflammation may help elucidate the role...

Matching Channels

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...

Systemic Sclerosis

Diffuse mesangial sclerosis

Amyotrophic lateral sclerosis ALS

B lymphocyte stimulator BlyS

Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.

Matching News

[Articles] Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study

We did not detect KIR4.1-specific IgG in serum or CSF from patients with multiple sclerosis or KIR4.1 loss from glia in multiple sclerosis lesions. Serological testing for KIR4.1-specific IgG is unlik...

SLU researcher receives $608,376 grant to design better clinical treatments for multiple sclerosis

Saint Louis University researcher Daniel Hawiger, M.D., Ph.D., has been awarded $608,376 from the National Multiple Sclerosis Society to gain a better understanding of how the autoimmune process that ...

Defining the clinical course of multiple sclerosis

Researchers have re-examined standardized multiple sclerosis descriptions published in 1996 to influence future research studies and clinical practice. Accurate clinical course descriptions (phenotype...

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Today Biogen Idec announced that the European Commission (EC) has granted marketing authorization for PLEGRIDY (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple scler...

Cell therapy for multiple sclerosis patients: Closer than ever?

For the first time, scientists generated induced pluripotent stem cells lines from skin samples of patients with primary progressive multiple sclerosis and further, they developed an accelerated proto...

Kessler Foundation receives MS Research Center Award from National MS Society

(Kessler Foundation) Kessler Foundation is the recipient of a Multiple Sclerosis Research Center Award from the National Multiple Sclerosis Society. John DeLuca, Ph.D., is the principal investigator f...

MS drug candidate shows new promise

Positive new data have been released on a drug candidate, RPC1063, for relapsing multiple sclerosis. According to the results from a six-month Phase 2 study of 258 multiple sclerosis patients, the dru...

[Articles] Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

TOPIC is to our knowledge the first study to report benefits of an available oral disease-modifying therapy in patients with early multiple sclerosis. These results extend the stages of multiple scler...

Matching PubMed Articles

The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis.

Patients with multiple sclerosis (MS) lose brain volume (BV) faster than healthy individuals.

Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network.

Approximately one-third of those with pediatric-onset multiple sclerosis (MS) experience cognitive impairment. Less is known concerning their change in cognitive functioning over time.

Characterizing cognitive function during relapse in multiple sclerosis.

To characterize neuropsychological (NP) test performance during multiple sclerosis (MS) relapse and recovery.

TIRC7 and HLA-DR axis contributes to inflammation in multiple sclerosis.

Interactions between TIRC7 (a novel seven-transmembrane receptor on activated lymphocytes) and its ligand HLA-DR might be involved in the inflammatory process in multiple sclerosis (MS).

Tracking changes over time in retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness in multiple sclerosis.

Neurodegeneration plays an important role in permanent disability in multiple sclerosis (MS).

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement